Calendario›FATE›Genetically engineered NK cells

Genetically engineered NK cells

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Ensayo de FATE THERAPEUTICS INC en Hematological Malignancy (del registro, en inglés).

Fase

no aplica

Estado

Interrumpido

Participantes

2

previstos

Centros

5

Fin del objetivo primario

abr 2020

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en oct 2019.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Incorporation of LTFU into the main interventional study.».

Qué mide

Overall Survival (OS) post-infusion (15 years post last treatment) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.

Más ensayos de FATE

Todos los de FATE, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04093622), actualizada en ago 2022.